|
|
|
|
Lancet study shows early breast cancer reduction
A large, independent phase III randomised study in women with early breast cancer has shown that adding capecitabine to a treatment regimen containing standard agents allows more women to live cancer-free for longer.This update outlines the pre-planned,...
|
|
|
Studies from D. Mahadevan and colleagues reveal new findings on epirubicin therapy
- (NewsRx.com) 'A Phase I study was initiated to investigate fixed dose rate gemcitabine (GEM) combined with epirubicin (EPI) given weekly or every other week, since, GEM given as a standard 30 minute infusion has modest activity (see also Epirubicin...
|
|
|
Gene Expression Profile Could Direct Breast Cancer Chemotherapy
Drug resistance in certain types of breast cancer has been linked to two genes that are overexpressed in the tumors of patients whose tumors reoccur following initially successful treatment with chemotherapeutic agents of the anthracycline class.The...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
- Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of...
|
|
|
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial
Blohmer JU et al.Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial.
|
|
|
A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: The TRAFIC trial
Sirohi B et al.The epirubicin with cisplatin and infusional 5-fluorouracil (5-FU) (ECisF) regimen was found to be highly active in the treatment of metastatic breast cancer and as neoadjuvant therapy. The UK TRAFIC (trial of adjuvant 5-FU infusional...
|
|
|
Future Treatment Choices Could Be Guided By Genes Linked To Breast Cancer Drug Resistance
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of...
|
|
|
Genes Linked To Breast Cancer Drug Resistance Could Guide Future Treatment Choices
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of...
|
|
|
For future breast cancer treatment
Scientists at Dana-Farber Cancer Institute have discovered a genetic signature that may help identify patients at high risk of breast cancer recurrence despite been treated with chemotherapy drugs.According to them, despite their resistance to drugs of the...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
BOSTON--Researchers at have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of the anthracycline class...
|
|
|
Gene discovery could guide future breast cancer treatment choices
London: Scientists at Dana-Farber Cancer Institute have discovered a genetic signature that may help identify patients at high risk of breast cancer recurrence despite been treated with chemotherapy drugs.According to them, despite their resistance to drugs...
|
|
|
Gene discovery could guide future breast cancer treatment choices
Scientists at Dana-Farber Cancer Institute have discovered a genetic signature that may help identify patients at high risk of breast cancer recurrence despite been treated with chemotherapy drugs.According to them, despite their resistance to drugs of the...
|
|
|
Genes found linked to breast cancer drug resistance
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumours that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
Researchers at have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumours that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of the anthracycline class, the...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
ScienceDaily (Jan.24, 2010) Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. Despite...
|
|
|
Breast cancer gene clue could save hundreds
Scientists have pinpointed the genes that stop common breast cancer drugs from working in a breakthrough that could save hundreds of lives a year.The discovery paves the way for a genetic test that identifies women likely to be resistant to the powerful...
|
|
|
Genes Linked to Breast Cancer Drug Resistance Could Guide Future Treatment
Source: Dana-Farber Cancer Institute Newswise Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
BOSTON--Researchers at have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of the anthracycline class...
|
|
|
Genes Linked to Breast Cancer Drug Resistance Could Guide Future Treatment
Newswise - Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
BOSTON--Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to...
|
|
|
Genes found linked to breast cancer drug resistance could guide future treatment choices
BOSTON--Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to...
|
|
|
Ch17CEP duplication predicted anthracycline benefit in early breast cancer
A prospective analysis of results of the UK National Epirubicin Adjuvant Trial indicate that chromosome 17 centromere enumeration probe duplication, and not HER2 or TOP2A duplication, was the best predictor of benefit from the addition of anthracyclines...
|
|
|
Ch17CEP duplication predicted anthracycline benefit in early breast cancer
A prospective analysis of results of the UK National Epirubicin Adjuvant Trial indicate that chromosome 17 centromere enumeration probe duplication, and not HER2 or TOP2A duplication, was the best predictor of benefit from the addition of anthracyclines...
|
|
|
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
Yun J et al.Both CX and ECX appear to be active as firstline chemotherapy for AGC, and the safety profiles are acceptable. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and...
|
|
|
Predictive markers of anthracycline benefit: A prospectively planned analysis of the UK National Epirubicin Adjuvant Trial
Bartlett JMS et al.The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of...
|
